Skip to content
Catalyst

Astragalus membranaceusFinding

Astragalus membranaceus decreases glycated haemoglobin (HbA1c)

lowersVery limited evidenceFinding

01 · The sentence it was drawn from

“Although AAD treatment significantly reduced levels of glycated hemoglobin A1c (HbA1c) (WMD=-1.77, 95% CI=-3.06 to -0.47, P=0.007, I(2)=90.8%), AI treatment failed to show significant efficacy (WMD=-0.28, 95% CI=-0.63 to 0.06, P=0.102, I(2)=83.8%).”
Quoted verbatim from The effect of Astragalus as an adjuvant treatment in type 2 diabetes mellitus: A (preliminary) meta-analysis.
This finding among the 64 findings on its endpoint

Astragalus membranaceus

Glycated haemoglobin (HbA1c)

lowers

Effect as reported

−1.77mean difference

CI −3.06 to −0.47

Who
Adults with type 2 diabetes mellitus; pooled controlled trials of Astragalus aqueous decoction as adjuvant treatment versus control group (13 studies, 1054 participants across both Astragalus subgroups)
Dose studied
not reported

Very limited evidencePMID 27269392 · 2016

02 · The study

Study
meta-analysis
Duration
not reported

Evidence, by strength

  • strong
  • moderate
  • limited
  • very limitedthis finding
  • insufficient

03 · The paper

Journal of ethnopharmacology
What else it reported1 finding · 0 compounds · 1 endpoint

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M704RSJK6C7CHKRGV2SQBM07